AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03058172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Odor presentation (for participants' perception)
Description: Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
Study NCT03058172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Image presentation (for participants' perception)
Description: Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
Study NCT03111355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: one nut a day for 2 months, no intervention for 2 months
Study NCT01347866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 intravenous infusion weekly starting at 110 mg.
Study NCT01347866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
Study NCT01347866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 intravenous infusion weekly starting at 95 mg.
Study NCT01347866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
Study NCT00899470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Saxagliptin and Metformin IR, Fasted
Description: Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
Study NCT00899470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin, Fasting
Description: Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
Study NCT00899470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Saxagliptin and Metformin IR, Fed
Description: Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
Study NCT00899470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin, Fed
Description: Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
Study NCT01508754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure treatment
Description: Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
Study NCT03605199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
Study NCT03634904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug bood sampling
Description: Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session
Study NCT02322684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Description: Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet once daily
Study NCT03905395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation and mindfulness
Description: Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
Study NCT01560442 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine and Methadone Hydrochloride
Description: To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravenous infusion
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil ( in FOLFOX)
Description: intravenous infusion
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine Oral Suspension
Description: Given PO
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil ( in FOLFOX)
Description: intravenous infusion
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin (in FOLFOX)
Description: intravenous infusion
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (in FOLFOX)
Description: intravenous infusion
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin (in FOLFOX)
Description: intravenous infusion
Study NCT01381718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: Given PO
Study NCT01381718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV or IM
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM
Study NCT03453190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Apremilast and Clobetasol
Description: Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
Study NCT00384176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (in FOLFOX)
Description: intravenous infusion
Study NCT00071422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study NCT00071422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given PO or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV
Study NCT02489565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study NCT01401257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 Low dose
Description: Liquid,5 ml, twice a day, 12-month treatment
Study NCT03544736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental: Nivolumab
Study NCT02572895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
Study NCT02572895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
Study NCT03544736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT03544736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy
Study NCT03544736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT03914625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy
Study NCT03914625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo testicular radiation therapy
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT02379390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Study NCT02379390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezalutamide
Study NCT02379390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Study NCT02379390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01401257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 Intermediate Dose
Description: Liquid,5 ml, twice a day, 12-month treatment
Study NCT02379390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02721251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
Study NCT02721251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: 16 week. the goal is 10% weight loss.
Study NCT01401257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 High Dose
Description: Liquid,5 ml, twice a day, 12-month treatment
Study NCT01401257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid,5 ml, twice a day, 12-month treatment
Study NCT01618188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study NCT02721251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Weight Loss
Description: Combined exercise and weight loss components of the other arms
Study NCT01618188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study NCT02151812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agent Paclitaxel-coated balloon
Description: After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
Study NCT02151812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® Please Paclitaxel-coated Balloon
Description: After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
Study NCT02161120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Finnish rye bread
Study NCT02161120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP rye bread
Study NCT02139917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional community based palliative care
Description: transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support
Study NCT03413137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal mpMRI-US Fusion prostate biopsy
Description: mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
Study NCT03413137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal mpMRI-US Fusion prostate biopsy
Description: using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
Study NCT02038231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully Program
Description: see Arm Description.
Study NCT02038231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education Program
Description: See Arm Description.
Study NCT04142008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walk with Me app
Description: For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
Study NCT03507478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPI1000013
Description: Foam insole
Study NCT00196131 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: morphine
Description: only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
Study NCT03095573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral-viewing CapsoCam device
Description: Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
Study NCT03095573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axial-viewing capsule
Description: Small bowel capsule endoscopy examination with the Axial-viewing capsule device
Study NCT03822221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 85º and knee at 20º
Description: With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
Study NCT03822221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 85º and knee at 60º
Description: With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
Study NCT03822221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 0º and knee at 20º
Description: With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
Study NCT03822221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 0º and knee at 60º
Description: With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
Study NCT01764295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1276
Study NCT01764295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Study NCT03783728 — intervention group
Intervention type: DRUG
Intervention: Rifapentine 600 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study NCT01764295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT03783728 — intervention group
Intervention type: DRUG
Intervention: Isoniazid 900 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study NCT01764295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03781674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 400mg
Description: Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
Study NCT03781674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 200mg
Description: Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
Study NCT03783728 — intervention group
Intervention type: DRUG
Intervention: Pyridoxine 50 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study NCT00976950 — intervention group
Intervention type: DRUG
Intervention: Tipranavir
Study NCT00976950 — intervention group
Intervention type: DRUG
Intervention: ritonavir
Description: low-dose
Study NCT03991559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manganese Chloride
Description: Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
Study NCT03781674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to progesterone 200mg
Description: Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
Study NCT03875963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic loaded bone filler
Description: Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
Study NCT03781674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to progesterone 200mg
Description: Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
Study NCT03781674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to progesterone 400mg
Description: Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age